Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials

[1] Pitt B(2001)The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI heart failure efficacy and survival study Cardiovasc Drugs Ther 15 79-87

[2] Williams G(2003)Eplerenone post-acute myocardial infarction heart failure E and survival study I. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309-1321

[3] Remme W(2011)Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (eplerenone post-acute myocardial infarction heart failure efficacy and survival study) substudy J Am Coll Cardiol 58 1958-1966

[4] Martinez F(2009)Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study Circulation 119 2471-2479

[5] Lopez-Sendon J(2018)Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study Clin Res Cardiol 107 49-59

[6] Zannad F(2018)Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial Clin Res Cardiol Ger 107 1192-1195

[7] Neaton J(1995)Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis Am J Cardiol 75 913-918

[8] Roniker B(2015)Circulating biomarkers of myocardial fibrosis: the need for a reappraisal J Am Coll Cardiol 65 2449-2456

[9] Hurley S(2014)Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study Eur Heart J 35 2295-2302

[10] Burns D(2000)Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators Circulation. 102 2700-2706

[1] Pitt B(2001)The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI heart failure efficacy and survival study Cardiovasc Drugs Ther 15 79-87

[2] Williams G(2003)Eplerenone post-acute myocardial infarction heart failure E and survival study I. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309-1321

[3] Remme W(2011)Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (eplerenone post-acute myocardial infarction heart failure efficacy and survival study) substudy J Am Coll Cardiol 58 1958-1966

[4] Martinez F(2009)Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study Circulation 119 2471-2479

[5] Lopez-Sendon J(2018)Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study Clin Res Cardiol 107 49-59

[6] Zannad F(2018)Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial Clin Res Cardiol Ger 107 1192-1195

[7] Neaton J(1995)Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis Am J Cardiol 75 913-918

[8] Roniker B(2015)Circulating biomarkers of myocardial fibrosis: the need for a reappraisal J Am Coll Cardiol 65 2449-2456

[9] Hurley S(2014)Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study Eur Heart J 35 2295-2302

[10] Burns D(2000)Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators Circulation. 102 2700-2706